| |
 |
 |
 |
 |
 |
 |
 |
 |
|
| HOME
> For Investors > The Company |
|
|
|
 |
 |
| |
| Corporate name : |
AnGes MG, Inc. |
| Head
office : |
4F, Saito Bio-Incubator, 7-7-15, Saito-asagi,
Ibaraki, Osaka, 567-0085 Japan |
| Established : |
December 17, 1999 |
| President and CEO
: |
Ei Yamada |
| Capitalization : |
9,653 million yen(at the end of December 2011) |
| Issued and
outstanding : |
122,333 shares(at the end of December 2011) |
| Number of
employees : |
71(to be consolidated at the end of December 2011) |
| Scope
of business : |
Research & development of genetic medicine |
|
 |
|
| |
| December
1999 : |
Founded as MedGene Co., Ltd. in Izumi-city, Osaka for research and development of gene and nucleotide based drugs and reagents for use in functional analyses of genetic medication. |
| June
2000 : |
Changed corporate name to MedGene Bioscience Co., Ltd. |
| August
2000 : |
Formed partnership with Ishihara Sangyo Kaisha, Ltd. on manufacturing and marketing of HVJ envelope vectors. |
| January
2001 : |
Established Ikeda Laboratory in Ikeda-city, Osaka. |
| January
2001 : |
Established Tokyo branch in Minato-ku, Tokyo. |
| January
2001 : |
Formed partnership with Daiichi Sankyo Co., Ltd. (former Daiichi Pharmaceutical Co., Ltd.) on development of HGF gene based drug in Japan for PAD. |
| July
2001 : |
Moved head office to Toyonaka-city, Osaka. |
| October
2001 : |
Founded AnGes, Inc. in the state of Maryland for clinical development in the US. |
| October
2001 : |
Changed corporate name to AnGes MG, Inc. |
| April
2002 : |
Expanded partnership with Daiichi Sankyo Co., Ltd. (former Daiichi Pharmaceutical Co., Ltd.) on development of HGF gene based drug to the US, Europe and Japan, in the fields of PAD and IHD. |
| June
2002 : |
Founded AnGes, Euro Ltd. (business development in Europe) in the county of Sussex, UK. |
| July
2002 : |
Founded GenomIdea Inc. in Toyonaka-city, Osaka for gene function analyses. |
| September
2002 : |
IPO : AnGes MG achieved listing on the Mothers markets of Tokyo Stock Exchange. |
| February
2003 : |
Moved head office of AnGes, Euro Ltd. to Surrey, UK. |
| September
2003 : |
Transferred HVJ envelope vectors business to GenomIdea, Inc. |
| September
2004 : |
Moved head office to Ibaraki-city, Osaka. |
| September
2004 : |
Moved head office of GenomIdea Inc. to Ibaraki-city, Osaka. |
| June
2005 : |
Formed partnership with Alfresa Pharma Corporation on development and marketing of NF-κB decoy oligonucleotides in the field of atopic dermatitis in Japan. |
| August
2005 : |
Formed partnership with Avontec GmbH, with a cross license arrangement, granting NF-κB decoy for psoriasis in Europe, and obtaining STAT-1 decoy for skin and respiratory diseases in Asia. |
| May
2006 : |
Formed partnership with Vical, Inc., investing into Vical’s Phase III program of a gene based drug, “Allovectin-7®”, for metastatic melanoma combined with an equity investment and grant of rights in Asia. |
| December
2006 : |
Formed partnership with BioMarin Pharmaceutical, Inc. on marketing and distribution of a product approved in the US, “Naglazyme®” (gulsulfase) for treatment of the genetic disease mucopolysaccharidosis VI in Japan. |
|
 |
|
| |
 Offices |
|
| Headquarters
: |
4F, Saito Bio-Incubator, 7-7-15, Saito-asagi,
Ibaraki, Osaka, 567-0085 Japan |
| Saito
Lab. : |
4F, Saito Bio-Incubator, 7-7-15, Saito-asagi,
Ibaraki, Osaka, 567-0085 Japan |
| Tokyo
branch : |
5F, Mita Suzuki Building, 5-20-14, Shiba, Minato-ku,
Tokyo, 108-0014 Japan |
|
|
|
| |
| Affiliated
subsidiaries |
|
| AnGes,
Inc. : |
10411 Motor City Dr., Suite 430, Bethesda,
Maryland 20817, USA |
| AnGes
Euro Limited : |
Suite 106, Airport House, Purley Way, Croydon, Surrey,
CR0 0XZ, UK |
| AnGes Healthcare Science Inc. : |
5F, Mita Suzuki Building, 5-20-14, Shiba, Minato-ku,
Tokyo, 108-0014 Japan |
| GenomIdea Inc. : |
4F, Saito Bio-Incubator, 7-7-15, Saito-asagi,
Ibaraki, Osaka, 567-0085 Japan
(Ikeda Lab)
1-8-31, Midorigaoka, Ikeda, Osaka, 563-8577 Japan |
|
|
|
|
|
